Unichem Amends 5 Billion Won Third-Party Rights Offering to Increase Operating Funds to 3 Billion Won, Confirming 11% Dilution to Largest Shareholder J&J People
Unichem amended its rights offering decision on July 21, 2026, maintaining the total 5 billion won raise but shifting the fund usage from 4 billion won for securities acquisition and 1 billion won for operations to 2 billion and 3 billion won respectively.
The payment date was moved forward one day to July 30, 2026, while the issuance of 1 million shares at 5,000 won per share remains unchanged, confirming an approximately 11.1% dilution for existing shareholders.
The 3 billion won operating funds will be used for raw material purchases, while the 2 billion won for securities acquisition remains contingent on an unspecified target, prolonging uncertainty.
The counterparty, largest shareholder J&J People, had negative equity of -3.8 billion won as of end-2025, indicating severe financial weakness and heightened counterparty risk.
Only one out of three outside directors attended the board resolution meeting, raising governance concerns regarding transparency.
All new shares are subject to a one-year lock-up, limiting short-term supply but not mitigating the long-term dilution impact.
[AI Summary]This amendment revises the capital use plan but does not resolve the fundamental risks: unclear use of proceeds, weak financial health of the largest shareholder, and an 11.1% dilution that erodes existing shareholder value, likely leading to negative short-term price pressure.
KOSPI Filing Information
[Correction of Description] Report on Major Events (Decision on Paid-in Capital Increase)